Posts Tagged ‘health insurance’

Right now, we are witnessing a great withdrawal from healthcare, especially for people living with obesity. Many people are losing health insurance coverage altogether because it has become unaffordable. Many others are finding that their insurance will no longer pay for the care they need – if they want the care, they must have the […]

Good luck if you want to make sense of headlines about health insurance and coverage trends for GLP-1 medicines. Peruse the headlines and you can find just about any narrative you want. “Rising health premiums push more small business to drop coverage,” according to Inc. “Employers are opting out of covering GLP-1s,” claims Hines, a […]

Business is apparently booming in the criminal trade for bogus obesity medicines. The Times (London) reports that criminals are selling dangerous weight-loss jabs on social media and in gyms. They write that: “Pharmaceutical bosses have issued a stark warning about medicines such as Mounjaro sold online without safety controls as gangs branch out from hard […]

Truveta this week published data that reveals striking growth in the use of GLP-1s by women with PCOS (polycystic ovary syndrome). Prescriptions for semaglutide or tirzepatide have risen by more than 700% in women with PCOS, according to their analysis. So don’t think that this is slipping right by the bean counters at drug benefit […]

It was remarkable and much needed. On the pre-convention day for ObesityWeek in Atlanta, ADA, OAC, and TOS began work to collaborate on models for obesity care that will begin to deliver on a scale that matches the urgency and scope of unmet medical need. TOS Vice-President Jonathan Purnell described the urgency of this to […]

A year ago, we had these wonderful new obesity medicines – semaglutide and tirzepatide – and nobody could get them. Demand had outstripped supply and we had a shortage. Earlier this year, the supply shortage for both drugs resolved, but now we face the same situation because of a different shortage. There is a shortage […]

Back in March 2024, we welcomed the news of a door opening ever so slightly for Medicare Part D plans to cover GLP-1s in people with obesity and heart disease. So 18 months later, it’s reasonable to ask, how’s that working out for everyone? A new research letter in JAMA gives us an answer, but […]

When the new administration announced in April that it would not be implementing expanded access to obesity medicines in Medicare, they suggested this would not be the final word. Yesterday, we got a hint of what might come. Paige Winfield Cunningham reported in the Washington Post that CMS has drafted a plan to allow Medicare […]

It is undeniable that obesity is a complex, chronic disease. When we gather people from all over the world who understand obesity, this is the number one thing everyone can agree upon. And yet, when we sit down to talk about models for health systems delivering obesity care, it is more likely that folks who […]

A new analysis from Milliman has a revelation for health plan managers complaining loudly about the burdensome costs of GLP-1s blowing up their budgets. They’re doing it wrong. Expenses for GLP-1s that can dramatically improve the health of persons with obesity simply do not have to break the bank for a health plan. In fact, […]